Tarsus Pharmaceuticals (TARS) Profit After Tax (2019 - 2026)

Tarsus Pharmaceuticals' Profit After Tax history runs 8 years deep, the most recent figure standing at -$7.6 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 69.68% year-over-year to -$7.6 million; the TTM figure through Mar 2026 stood at -$48.5 million (up 53.75% YoY), while the FY2025 annual figure was -$66.2 million, up 42.61% from the prior year.
• Profit After Tax for Q1 2026 stood at -$7.6 million, up from -$8.2 million in the prior quarter.
• The five-year high for Profit After Tax was -$5.7 million in Q2 2022, with the low at -$41.8 million in Q4 2023.
• The 5-year median for Profit After Tax is -$22.9 million (2024), against an average of -$22.8 million.
• The sharpest annual moves came in 2023 and 2026: Profit After Tax sank 447.17% in 2023, then soared 69.68% in 2026.
• Tarsus Pharmaceuticals' Profit After Tax stood at -$13.7 million in 2022, then slumped by 205.93% to -$41.8 million in 2023, then soared by 45.18% to -$22.9 million in 2024, then surged by 64.37% to -$8.2 million in 2025, then gained by 6.43% to -$7.6 million in 2026.
• Business Quant data shows TARS's Profit After Tax at -$7.6 million in Q1 2026, -$8.2 million in Q4 2025, and -$12.3 million in Q3 2025.